On July 7, Duality Biotherapeutics-B declined 5.07% in regular trading, trading at 213.4 HKD/share, with turnover of HKD 388 million. The pullback came after the stock posted substantial gains in prior sessions, including a 15.45% surge on July 2 and a 9.01% rise on July 6, driven by its Science and Technology Innovation Board IPO status advancing to inquiry stage and sustained ADC pipeline catalysts.

The broader biotech sector came under significant selling pressure, with multiple major names retreating in tandem. Within the Biotechnology sector, 3SBIO fell 6.94%, Akeso fell 4.51%, Innovent Bio fell 3.87%, BeiGene fell 3.57%, and SKB Bio fell 2.58%, reflecting widespread profit-taking across the industry following the sector's strong rally earlier in the week.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)